Acute tubular necrosis (ATN) and acute interstitial nephritis (AIN) are two of the most common intrinsic causes of acute kidney injury, but they involve different parts of the kidney, arise from different triggers, and call for different management. ATN damages the tubular cells that line the tiny filtration tubes inside the kidney, usually because of reduced blood flow or direct toxic exposure. AIN is an inflammatory reaction in the tissue surrounding those tubes, most often sparked by a drug the immune system decides to attack. The distinction matters because AIN can respond to steroids if caught early, while ATN has no targeted treatment and relies on removing the underlying cause and waiting for the kidney to heal on its own.
How Common Are They
Both conditions are more common than many people realize, yet AIN in particular tends to be underdiagnosed. AIN is estimated to account for roughly 15 to 20 percent of all cases of acute kidney injury, though it shows up in only about 3 percent of all kidney biopsies and around 13.5 percent of biopsies performed specifically to investigate sudden kidney failure.1PubMed Central. Acute interstitial nephritis – a reappraisal and update The gap between estimated prevalence and biopsy rates tells you something important: many cases are never biopsied, so many go unconfirmed.
ATN, meanwhile, is widely regarded as the single most frequent cause of intrinsic acute kidney injury in hospitalized patients, particularly in intensive-care settings where low blood pressure, sepsis, and nephrotoxic drugs converge. In one large kidney biopsy series of nearly 9,000 cases, ATN and AIN turned up at comparable rates of about 1.6 percent and 1.9 percent, respectively.2Journal of Korean Medical Science. Long-term Renal Outcome of Biopsy-proven Acute Tubular Necrosis and Acute Interstitial Nephritis Those biopsy numbers underrepresent ATN’s true frequency, because clinicians often diagnose ATN on clinical grounds without performing a biopsy, reserving the procedure for situations where the cause of kidney injury is uncertain.
What Goes Wrong in Each Condition
ATN is fundamentally a story of cell injury and death. The tubular cells that line the kidney’s filtering network are metabolically active and vulnerable to drops in oxygen supply. When blood flow to the kidney falls sharply, whether from severe blood loss, a major drop in blood pressure during surgery, or sepsis, those cells start dying. The process involves a cascade of hemodynamic changes, inflammation, and damage to both the inner lining of small blood vessels and the tubular cells themselves.3PubMed Central. Cellular pathophysiology of ischemic acute kidney injury Toxic exposures can cause the same kind of cell death through a more direct route: certain antibiotics, contrast dyes used in imaging, and other nephrotoxic chemicals can poison tubular cells outright.
AIN operates through a completely different mechanism. It is an immune-mediated process, essentially an allergic or hypersensitivity reaction that takes place inside the kidney. In the most common scenario, drug-induced AIN, the reaction typically develops seven to ten days after exposure to the offending drug. The kidney’s immune cells process fragments of the drug as foreign, activate T cells, and set off an inflammatory cascade driven by various signaling molecules called cytokines.4PubMed. Mechanisms of Drug-Induced Interstitial Nephritis The inflammation concentrates in the interstitium, the connective tissue between the tubules, rather than in the tubular cells themselves. Over time, though, that swelling and immune activity can squeeze and damage the tubules from the outside.
Different Triggers, Different Risk Profiles
The causes of ATN split neatly into two categories: ischemic and toxic. Ischemic ATN results from anything that significantly reduces blood supply to the kidneys. This includes major surgery, severe dehydration, hemorrhage, heart failure, and sepsis. Toxic ATN results from direct chemical damage to tubular cells, commonly caused by aminoglycoside antibiotics, certain chemotherapy agents, the antifungal amphotericin B, and iodinated contrast dyes used in CT scans and cardiac catheterizations. In practice, many hospitalized patients face both ischemia and toxic exposure simultaneously, making ATN the dominant form of kidney injury in critical care units.
AIN has a broader range of triggers, though drugs are by far the most common. The classic offenders include antibiotics (particularly penicillins and cephalosporins), nonsteroidal anti-inflammatory drugs (NSAIDs), and proton pump inhibitors, the acid-suppressing medications taken by millions of people for heartburn and reflux.5PubMed Central. Acute interstitial nephritis due to proton pump inhibitors The proton pump inhibitor connection is worth highlighting because these drugs are available over the counter and widely used on a long-term basis, yet most people taking them have never heard of AIN as a possible side effect. Beyond drugs, AIN can also be triggered by infections, autoimmune diseases like lupus or sarcoidosis, and less commonly, by causes that remain unknown.
A newer and increasingly recognized trigger is immune checkpoint inhibitor therapy, which is used in cancer treatment. These drugs work by unleashing the immune system against tumors, but that same unleashing can turn against the kidneys. Kidney injury from checkpoint inhibitors occurs in roughly two to five percent of patients receiving them, and the most common finding on biopsy is acute tubulointerstitial nephritis. The risk goes up when patients are also taking other AIN-associated drugs like proton pump inhibitors or NSAIDs, or when they receive combination immunotherapy.6PubMed. Immune checkpoint inhibitor-associated nephritis-treatment standard
How Doctors Tell Them Apart at the Bedside
Distinguishing ATN from AIN without a biopsy is genuinely difficult, and misdiagnosis is common. Both conditions cause a rise in creatinine (the blood marker used to track kidney function), and both can reduce urine output. The clinical context provides the first clue: a patient in the ICU with sepsis and low blood pressure who develops kidney failure is far more likely to have ATN. A patient who recently started a new antibiotic and now has a rising creatinine may have AIN. But these situations overlap constantly, because the same patient can be both septic and on multiple new medications.
The classic teaching about AIN includes a triad of fever, rash, and eosinophilia (elevated eosinophil white blood cells). In reality, the full triad appears in a minority of AIN cases, making it unreliable for diagnosis. Eosinophils in the urine were once considered a hallmark of AIN, but studies over the years have shown that urine eosinophils lack both the sensitivity and specificity to be trustworthy on their own. Their presence might raise suspicion, but their absence does not rule anything out.
Urine Sediment Under the Microscope
Examining a urine sample under the microscope remains one of the most useful bedside tools for separating ATN from AIN. In ATN, the hallmark finding is muddy brown granular casts, which are clumps of dead tubular cells and debris that have been shed into the urine and molded into the shape of the tubules. A study comparing urine findings with biopsy results found that muddy brown granular casts had a sensitivity of 78 percent and a specificity of 100 percent for biopsy-proven tubular injury. In other words, when these casts are present, the diagnosis of ATN is essentially confirmed; when they are absent, ATN is not ruled out but other diagnoses become more likely.7Journal of the American Society of Nephrology. Histopathological Confirmation of Acute Tubular Injury in Patients with “Muddy Brown” Granular Casts in the Urinary Sediment
AIN, by contrast, tends to show white blood cells in the urine, sometimes white blood cell casts, and occasionally red blood cells. The sediment is often described as “active” but lacks the coarse granular casts of ATN. The problem is that white cells in the urine are nonspecific and can appear with urinary tract infections, glomerular diseases, and other conditions.
Fractional Excretion of Sodium and Urea
Fractional excretion of sodium (FENa) is a calculation that compares how much sodium the kidney filters versus how much it excretes, giving a rough sense of whether the kidney’s tubules are still working to reclaim sodium (suggesting a prerenal cause like dehydration) or have lost that ability (suggesting intrinsic damage like ATN). A FENa above about 2 percent traditionally points toward ATN. In patients not on diuretics, one study found FENa had a sensitivity of 78 percent and specificity of 75 percent for distinguishing transient from persistent kidney injury. However, in patients receiving diuretics, those numbers dropped substantially, with sensitivity falling to 58 percent, making FENa much less useful in that common clinical scenario.8PubMed. Diagnostic performance of fractional excretion of urea and fractional excretion of sodium in the evaluations of patients with acute kidney injury with or without diuretic treatment
The fractional excretion of urea (FEUrea) was proposed as an alternative that would remain accurate even in patients taking diuretics, since diuretics affect sodium handling but should not affect urea handling as much. In practice, FEUrea has not lived up to expectations. It lacks specificity and does not reliably replace FENa in diuretic-treated patients.9PubMed. Diagnostic performance of fractional excretion of urea and fractional excretion of sodium in the evaluations of patients with acute kidney injury with or without diuretic treatment In one study of patients with liver disease and kidney injury, FENa performed reasonably well for distinguishing ATN-type injury from non-ATN causes, while FEUrea added little additional diagnostic value.10PubMed Central. Fractional Excretion of Sodium and Urea in Differentiating Acute Kidney Injury Phenotypes in Decompensated Cirrhosis
The bottom line for these indices is that they are helpful when the clinical picture is clear but far from definitive when things are ambiguous, which is exactly when you need them most.
Emerging Biomarkers
Researchers have been working to develop blood and urine tests that can identify the specific type of kidney injury without needing a biopsy. For ATN, two biomarkers have received the most attention: NGAL and KIM-1. Both are proteins released by injured tubular cells, and their levels in the urine rise when tubular damage is occurring. In patients with biopsy-proven tubular necrosis, urinary KIM-1 and NGAL levels were significantly higher than in patients without tubular injury, and both correlated with the extent of damage seen on biopsy.11J. Bras. Nefrol.. Biomarkers of acute kidney injury in patients with nephrotic syndrome These biomarkers show promise for early detection of kidney injury, though the evidence is still building and they are not yet part of routine clinical practice everywhere.12PubMed Central. Could KIM-1 and NGAL levels predict acute kidney injury after paracentesis? – preliminary study
For AIN, a different set of biomarkers appears to be more useful. Because AIN is driven by immune activation rather than direct cell death, the urine of AIN patients contains elevated inflammatory signaling molecules. In particular, urine levels of TNF-alpha and IL-9 have been found to be consistently higher in patients with AIN compared to those with ATN, glomerular diseases, or diabetic kidney disease. Patients in the highest quartile of TNF-alpha levels had roughly eleven times the odds of having AIN compared to those in the lowest quartile, and those with the highest IL-9 levels had about seven and a half times the odds. Adding these biomarkers to clinicians’ pre-biopsy clinical judgment significantly improved diagnostic accuracy, pushing the area under the curve from 0.62 to 0.84.13PubMed Central. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis That last number is striking because it suggests that even experienced kidney specialists are only modestly better than a coin flip at guessing AIN before the biopsy, but the addition of these two biomarkers brings accuracy up to a level that could reduce the need for invasive tissue sampling.
Why the Distinction Changes Treatment
This is where the ATN-versus-AIN question has the most practical weight. ATN does not have a specific treatment. The strategy is to remove or correct whatever caused the injury, whether that means restoring blood pressure, stopping a nephrotoxic drug, or treating an underlying infection, and then support the patient while the kidneys attempt to regenerate. In severe cases, temporary dialysis may be needed, but the dialysis itself does not accelerate recovery. A large trial found that intensive dialysis (six sessions per week, or higher-volume continuous filtration) did not improve mortality, speed kidney recovery, or reduce organ failure compared to a standard three-times-per-week schedule.14PubMed Central. Intensity of renal support in critically ill patients with acute kidney injury A separate prospective study of critically ill patients with ATN who required dialysis found that neither patient characteristics nor the mode or duration of dialysis predicted whether kidneys would recover.15PubMed. Renal recovery from acute tubular necrosis requiring renal replacement therapy: a prospective study in critically ill patients The kidney either heals or it does not, and doctors are largely along for the ride.
AIN, in contrast, has a time-sensitive treatment window. The first and most important step is stopping the offending drug if one can be identified. Beyond that, corticosteroids can dampen the inflammatory process and improve outcomes, but timing is critical. One study found that delaying steroid treatment by an average of 34 days after stopping the causative drug led to worse kidney function recovery compared to starting steroids within the first two weeks. Biopsies in the delayed group showed progression to interstitial fibrosis, a kind of scarring that is largely irreversible.16PubMed. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis Another study confirmed this pattern, finding that delayed steroid treatment and the presence of extensive fibrosis on biopsy (more than half the tissue affected) were both independently associated with incomplete kidney recovery at six months.17PubMed Central. Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis
The implication is clear: if AIN is misdiagnosed as ATN and managed with a wait-and-see approach, the window for steroid treatment narrows, fibrosis advances, and the patient may end up with permanently reduced kidney function. Conversely, if ATN is misdiagnosed as AIN and steroids are given unnecessarily, the steroids will not help and may introduce side effects, particularly in critically ill patients who are already vulnerable to infections and metabolic complications.
When a Biopsy Becomes Necessary
Given the limitations of urine tests, blood markers, and clinical guesswork, kidney biopsy remains the gold standard for distinguishing ATN from AIN. Under the microscope, the two conditions look very different. ATN shows loss and flattening of tubular epithelial cells, with cellular debris clogging the tubular lumens. AIN shows inflammatory cells (lymphocytes, sometimes eosinophils) infiltrating the interstitium, with edema and relatively preserved tubular architecture, at least early on.
Not every case of acute kidney injury warrants a biopsy, though. The procedure carries risks including bleeding, and it is usually reserved for situations where the clinical diagnosis is uncertain, kidney function is not recovering as expected, or AIN is suspected and a tissue diagnosis would change management. In many straightforward ATN cases, such as a post-surgical patient with low blood pressure whose kidneys are recovering on their own, a biopsy adds risk without changing the plan. But when a patient has been started on new medications, creatinine is climbing without a clear ischemic or toxic explanation, and stopping the suspected drug has not helped, a biopsy can make the difference between watching and waiting versus starting steroids while there is still time.
Long-Term Kidney Outcomes
Both ATN and AIN can lead to chronic kidney disease if the injury is severe enough or prolonged. For ATN, the repair process after ischemic injury can be either adaptive, restoring normal tubular function, or maladaptive, leading to fibrosis and a permanent decline in kidney function.18PubMed Central. Cellular pathophysiology of ischemic acute kidney injury Patients who survive a severe episode of ATN requiring dialysis have an elevated risk of progressing to chronic kidney disease even if they initially recover enough to stop dialysis. The severity of the initial injury, the number of recurrent episodes, and the presence of pre-existing kidney disease all influence long-term trajectory.
For AIN, incomplete recovery is closely linked to how quickly the offending agent is removed and whether steroids are started in time. The fibrosis that develops when AIN is allowed to smolder represents permanent tissue remodeling that no current treatment can reverse. Patients who receive a late diagnosis or whose AIN goes unrecognized may present months later with unexplained chronic kidney disease that traces back to an episode of unresolved interstitial inflammation.
ATN and AIN in Children
The ATN-versus-AIN distinction also applies in pediatric populations, though the balance of causes shifts. NSAIDs are a notable culprit in children, capable of causing both ATN and AIN depending on the mechanism involved. In one study of over a thousand children with acute kidney injury, NSAID-associated kidney injury accounted for about 2.7 percent of all cases, with 21 children showing features of tubular necrosis and 6 showing features of interstitial nephritis.19PubMed Central / Elsevier. Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children NSAIDs can damage the kidney through multiple pathways: by reducing blood flow (which can cause ischemic ATN), by directly injuring tubular cells, or by triggering an immune-mediated interstitial reaction. This dual potential makes NSAIDs an interesting case where a single drug class can produce either condition, and the clinical picture may not immediately clarify which one is present.
Children are also less likely to undergo kidney biopsy than adults, so the diagnosis often rests more heavily on clinical context and response to treatment. A child who develops kidney injury after ibuprofen use and improves promptly after stopping the drug may never receive a tissue diagnosis, while one whose function does not recover will be biopsied to guide further management.
Why AIN Gets Missed So Often
AIN’s reputation as an underdiagnosed condition is well earned. Several features of the disease conspire to keep it hidden. The classic triad of fever, rash, and eosinophilia is more the exception than the rule, so doctors who rely on those signs will miss many cases. The offending drug may have been started weeks or even months before kidney function begins to decline, making the temporal connection less obvious than it is with, say, contrast dye and ATN. Proton pump inhibitors are a prime example: a patient may have been taking one for months before AIN develops, and neither the patient nor the physician connects the dots.20PubMed Central. Acute interstitial nephritis due to proton pump inhibitors
There is also a threshold-of-suspicion problem. In hospitals, when kidney function deteriorates, the most common reflexive assumption is ATN, because ATN is the most frequent cause in that setting. Clinicians may mentally file the case as ATN and pursue supportive care without seriously considering AIN until the kidneys fail to recover on the expected timeline. By then, weeks may have passed, fibrosis may have set in, and the window for effective steroid treatment has narrowed or closed. The pre-biopsy diagnostic accuracy of experienced clinicians for AIN is only modestly above chance, as the biomarker research has shown, which reinforces the case for greater use of either biopsy or emerging urine biomarkers when the cause of kidney injury is not clear-cut.21PubMed Central. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Checkpoint Inhibitors and the Blurring of Categories
Cancer immunotherapy has introduced a new wrinkle into the ATN-versus-AIN framework. Immune checkpoint inhibitors can cause kidney injury that shows up on biopsy as acute tubulointerstitial nephritis, a hybrid pattern where both the tubules and the interstitium are involved. The risk rises when patients are simultaneously taking other drugs known to cause AIN, such as proton pump inhibitors or NSAIDs, and when combination immunotherapy is used.22PubMed. Immune checkpoint inhibitor-associated nephritis-treatment standard Managing these cases is complicated because oncologists may be reluctant to stop a cancer drug that is working, while nephrologists may be reluctant to add steroids that could theoretically blunt the anti-tumor immune response. The growing number of patients on these therapies means that kidney specialists are increasingly encountering cases that do not fit neatly into the traditional ATN or AIN box, pushing the field toward more routine biopsy and more nuanced treatment algorithms.